Synapse - Eytan Stein

Results (371)

Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center

Meeting Abstract

Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
Blood (2024)

Fulltext@MSK | Save

Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies

Meeting Abstract

Lin, R. J.; Kim, S. J.; Brown, S.; Hanley, D. M.; Engstler, D. E.; Politikos, I.; Gyurkocza, B.; Tamari, R.; Papadopoulos, E. B.; Saldia, A.; more...
Blood (2024)

Fulltext@MSK | Save

Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes/neoplasms (MDS): An analysis from the international consortium for MDS (icMDS) validate database

Meeting Abstract

Rolles, B.; Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stempel, J. M.; Lanino, L.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
Blood (2024)

Fulltext@MSK | Save

Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment

Meeting Abstract

DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
Blood (2024)

Fulltext@MSK | Save

Outpatient vs inpatient HiDA consolidation for AML: The MSKCC experience

Meeting Abstract

Boussi, L.; Burton, H.; Derkach, A.; Nemirovsky, D.; Ciervo, J.; Tallman, M. S.; Stein, E. M.; Cai, S.
Blood (2024)

Fulltext@MSK | Save

A phase 1, open-label, dose escalation and dose expansion, multicenter clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lomonitinib (ZE46-0134) in adults with FLT3-mutated relapsed or refractory acute myeloid leukemia

Meeting Abstract

Lin, T. L.; Koenig, K. L.; Swords, R. T.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; more...
Blood (2024)

Fulltext@MSK | Save

A randomized phase 2 trial of 28-day (Arm A) versus 14-day (Arm B) schedule of venetoclax + azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years

Meeting Abstract

Borate, U.; Huang, Y.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; more...
Blood (2024)

Fulltext@MSK | Save

The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study

Meeting Abstract

Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
Blood (2024)

Fulltext@MSK | Save

Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia

Meeting Abstract

Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; more...
Blood (2024)

Fulltext@MSK | Save

River-52: A multicenter, open-label clinical trial of RVU120 in patients with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia

Meeting Abstract

Papayannidis, C.; Madry, K.; Centkowski, P.; Prejzner, W.; Butrym, A.; Chraniuk, D.; Saba, C.; Angelosanto, N.; Curley, R.; Nogai, H.; more...
Blood (2024)

Fulltext@MSK | Save

Eytan Moshe Stein

Results (371)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract